Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has informed Cortex Pharmaceuticals that it is placing a clinical hold on trials of the company's lead product candidate CX717 which is being developed as a therapeutic for a number of disorders of the central nervous system.
Subscribe to our email newsletter
The action taken by the FDA is related to concerns over some preclinical animal data and not results from any human clinical trials, the company said.
“Until Cortex receives the formal notification and has had a chance to review its contents, it is unable to describe the exact terms of the notice,” the company said in a statement.
The company has so far only been informed of the clinical hold via a telephone call but should receive formal written notification within the next 7-10 days.
CX717 is in development for the treatment of attention deficit hyperactivity disorder, schizophrenia, Alzheimer’s disease and narcolepsy.